Topotecan Dosing Guidelines in Ovarian Cancer: Reduction and Management of Hematologic Toxicity

Topotecan Dosing Guidelines in Ovarian Cancer: Reduction and Management of Hematologic Toxicity Deborah K. Armstrong Oncologist 2004; 9: 33-42 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in gynecologic oncology and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Describe the hematologic safety profile of topotecan in patients with relapsed ovarian cancer. List the risk factors for increased hematologic toxicity after topotecan therapy. Discuss topotecan dose determination and the management of hematologic toxicity in higher-risk ovarian cancer patients. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Jan. 30, 2004 Most Recent Review: Jan. 30, 2004* Most Recent Update: Jan. 30, 2004 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.